Trial Profile
A Double-Blind Placebo-Controlled Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults With DSM-5 Attention Deficit Hyperactivity Disorder (ADHD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Jun 2021
Price :
$35
*
At a glance
- Drugs Mazindol (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Proof of concept; Therapeutic Use
- Sponsors NLS Pharma Ltd
- 19 Mar 2018 Results (n=85) assessing evaluate the efficacy of mazindol CR in adults with ADHD, were published in the CNS Drugs.
- 31 Oct 2017 According to an NLS Pharma media release, new data from this trial will be presented at the 2017 American Academy of Child & Adolescent Psychiatry (AACAP) Annual Meeting and at 2018 American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting.
- 31 May 2017 Results (n= 85) from this study published in a NLS Pharma Media Release.